Editas Medicine said today its lead candidate EDIT-101, an in vivo CRISPR gene editing treatment for Leber congenital amaurosis-10 (LCA10), showed positive initial clinical data showing it to be safe, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback